Core Viewpoint - The company, Chongqing Pharmaceutical Holdings (重药控股), currently operates solely within the domestic market and has not yet expanded its business overseas despite encouragement from the healthcare bureau for pharmaceutical and medical device exports [2] Group 1 - Investors inquired about the company's potential for overseas expansion in pharmaceuticals and medical devices [2] - The company confirmed that all its business activities are currently conducted within China [2]

Core Viewpoint - The company emphasizes its commitment to managing inter-subsidiary operations and has established relevant management systems to enhance operational efficiency [1] Group 1: Management Practices - The company has implemented management systems to oversee business operations among its subsidiaries [1] - Annual internal control audits are conducted by third-party organizations, which provide specialized reports [1] - Efficiency management has been integrated into the core management plan to optimize resource allocation and business collaboration [1]

证券代码：000950 证券简称：重药控股 公告编号：2026-004 重药控股股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.本次股东会没有出现否决议案的情形。 2.本次股东会不涉及变更前次股东会决议。 一、会议召开情况 （一）现场会议召开时间：2026 年 1 月 19 日（星期一）14:30。 网络投票时间：2026 年 1 月 19 日。其中： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2026 年 1 月 19 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2026 年 1 月 19 日 9:15-15:00。 （二）会议召开地点：重庆市渝北区金石大道 303 号公司会议室。 （二）出席（列席）现场会议的其他人员 公司部分董事、高级管理人员和公司聘请的见证律师出席和列席了本次股东 会现场会议。 （三）会议召开方式：现场投票和网络投票相结合的方式。 （四）会议召集人：公司董事会。 （五）现场会议主持 ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于重药控股股份有限公司 2026 年第一次临时股东会的 律师见证法律意见书 致：重药控股股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）接受重药控股股份有限公 司（以下简称"公司"）的委托，指派律师列席公司于 2026 年 1 月 19 日召开的 公司 2026 年第一次临时股东会（以下简称"本次股东会"）。根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股东会规则》和《深圳证券交易所股票上市规则》等现行有 关法律、法规、规范性文件以及《重药控股股份有限公司公司章程》（以下简称 "《公司章程》"）的规定，本所律师对公司本次股东会的召集和召开程序、召集 人、出席会议人员的资格、表决程序的合法性、有效性等进行了认真的审查，并 出具本法律意见书。 本所律师根据出席本次股东会所掌握的事实和公司提供的文件资料，按照现 行法律、法规的要 ...

Core Viewpoint - The company emphasizes its focus on improving cash flow management and enhancing research and development capabilities to address challenges in the pharmaceutical distribution industry [1] Group 1: Business Operations - The company operates in the pharmaceutical distribution industry, primarily engaged in the wholesale and retail of drugs and medical devices [1] - Recent efforts have been made to strengthen the collection of accounts receivable through enhanced assessment and collection measures [1] Group 2: Financial Management - The company has implemented measures to improve cash flow from operating activities, including better procurement management and continuous enhancement of credit management [1] Group 3: Research and Development - The company is increasing investment in research and development by introducing professional talent, deepening industry-academia-research cooperation, and optimizing R&D processes [1] - Continuous progress in new product development is being pursued to address issues related to R&D investment and capabilities [1]

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.19% on January 15, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - Notable gainers included: - RunDa Medical (603108) with a closing price of 20.04, up 1.83% and a trading volume of 700,800 shares [1] - LiuYao Group (603368) closed at 18.58, up 0.60% with a trading volume of 79,700 shares [1] - LaoBaiXing (603883) closed at 16.11, up 0.50% with a trading volume of 226,200 shares [1] - Significant decliners included: - Huaren Health (301408) closed at 23.81, down 19.99% with a trading volume of 491,100 shares [2] - ShangYu PingMin (301017) closed at 18.50, down 13.75% with a trading volume of 373,900 shares [2] - YaoYiGou (300937) closed at 37.40, down 11.79% with a trading volume of 121,400 shares [2] Capital Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 990 million yuan from institutional investors, while retail investors had a net inflow of 977 million yuan [2] - The table of capital flow indicates that: - LaoBaiXing (603883) had a net inflow of 46.10 million yuan from institutional investors [3] - JiuZhouTong (600998) had a net inflow of 40.43 million yuan from institutional investors [3] - RunDa Medical (603108) had a net inflow of 37.80 million yuan from institutional investors [3]

（文章来源：证券日报） 证券日报网讯 1月14日，重药控股发布公告称，公司将于2026年1月19日召开2026年第一次临时股东 会。 ...

Group 1 - The FDA has approved a dry powder inhaler (DPI) developed by a Chinese pharmaceutical company, marking a significant entry into the international mainstream market for high-end complex formulations [1][4] - The approved product is a combination medication (bronchodilator and inhaled corticosteroid) used for the regular treatment of reversible airway obstructive diseases, including asthma in adults and children [1][4] - Runsheng Pharmaceutical, established in October 2014, focuses on the research and production of inhalation delivery systems for respiratory diseases and has a rich pipeline of products [1][4] Group 2 - Chongqing Yaoyou Pharmaceutical, a subsidiary of Zhongyao Holdings, has signed a licensing agreement with Pfizer for the exclusive development and commercialization rights of GLP-1R agonists, including YP05002, across all indications globally [2] - Yaoyou Pharmaceutical has received an upfront payment of $15 million from Pfizer as part of this agreement [2]

证券代码：000950 证券简称：重药控股 公告编号：2026-003 重药控股股份有限公司 关于召开 2026 年第一次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重药控股股份有限公司（以下简称"公司"）于 2025 年 12 月 31 日在《中国 证 券 报 》 《 证 券 时 报 》 《 证 券 日 报 》 《 上 海 证 券 报 》 及 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上刊登了《关于召开 2026 年第一次临时股东会的 通知》（公告编号：2025-093）。本次股东会将采用现场投票与网络投票相结 合的方式进行，现再次将本次股东会的有关事项提示如下： 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》 的有关规定。 4、会议时间： （ ...

Group 1 - The company is actively advancing its digital transformation by leveraging AI to enhance industrial upgrades [1] - The company has completed the privatization deployment of AI computing power and large models, and is implementing a unified AI capability platform [1] - The integration of AI is being applied internally in areas such as operations, risk control, marketing, finance, and logistics, while externally it is enhancing clinical auxiliary diagnosis applications in traditional Chinese medicine and specialized diseases [1]